Plasma Derived Therapy Market - By Product (Immunoglobulins, Coagulation Factors, Albumin), Application (Hemophilia, Primary Immunodeficiency Diseases, Idiopathic/Immune Thrombocytopenic Purpura (ITP)), Global Forecast, 2023-2032

Plasma Derived Therapy Market Size

Plasma Derived Therapy Market size was valued over USD 16.8 billion in 2022 and will grow momentously at 7.5% CAGR between 2023 and 2032. Increasing prevalence of rare diseases including primary immunodeficiency diseases, idiopathic thrombocytopenic purpura (ITP), von Willebrand disease, and others are one of the major factors contributing to the growth of market across the globe. The higher incidence rate of primary immunodeficiency diseases and von Willebrand disease that can lead to severe health conditions will drive the demand for plasma derived therapy.
 

According to the report published by the Centres for Disease Control and Prevention in 2021, around 3.2 million people in U.S. suffer from von Willebrand disease. Hence, the availability of effective plasma derived therapy that offers effective solution against these rare diseases will lead to unprecedented growth opportunities to the plasma derived therapy industry in the forthcoming years.
 

Plasma-derived therapy is a highly effective treatment derived from human plasma that is widely used to treat rare and complex diseases. Plasma-derived therapies aid in the replacement of deficient or missing proteins, allowing people to live healthier and more productive lives. Plasma-derived products primarily consist of coagulation factors, albumin, and immunoglobulins, that are used as life-saving therapeutics to treat variety of genetic and life-threatening diseases worldwide.
 

COVID-19 Impact

The incidence of coronavirus infection has affected millions of individuals worldwide that had temporarily impacted the plasma donation globally, also affected the plasma derived therapy market. However, due to unavailability of specific treatment medicine and vaccine against COVID-19, research institutes have focused on plasma-based therapy to identify any role in treating the COVID-19. Further, in March 2020, the Houston Methodist Hospital, U.S., announced use of plasma fractionation for treatment of COVID-19 and became the first hospital in U.S. to offer plasma derived therapy among COVID-19 patients. Therefore, high incidence rate of COVID-19 patients has resulted in increased demand for plasma derived immunoglobulins, thereby driving growth of the overall market.

Plasma Derived Therapy Market Trends

• The increasing investments by the plasma industry in research and development activities to create innovative plasma therapies which result in cutting-edge medical procedures that help patients will act as a positive impact rendering factor for market progress. For instance, Grifols dedicated its USD 360 million to increase its capacity for producing plasma-derived treatments. With the support of this investment, the company has been able to improve its plasma fractionation and purification capabilities.
   
• Plasma-derived therapy industry is driven by the growing adoption of immunoglobulin across the world. Plasma-derived immunoglobulins demand has increased owing to an increase in the recognition and treatment of immune deficiencies. It has emerged as an important treatment option in a variety of clinical settings, including autoimmune conditions and acute inflammatory.
   

Plasma Derived Therapy Market Analysis

Based on product, the global market is classified into immunoglobulins, coagulation factors, albumin, and other products. Immunoglobulin market held 48.1% business share in 2022.
 

• The segment is projected to witness significant growth owing to increasing use of immunoglobulins for the treatment of several complex diseases globally. Also, growing awareness about the advanced procedures among the population coupled with increasing adoption of immunoglobulin for treatment of several diseases is anticipated to boost the demand for immunoglobulin therapy.
   
• Further, the segment growth is attributed to increasing prevalence of Kawasaki disease (KD), immune thrombocytopenic purpura (ITP), primary immunodeficiency, and other neuromuscular diseases among population.
   

Based on application, the plasma derived therapy market is categorized into primary immunodeficiency diseases, haemophilia, idiopathic thrombocytopenic purpura (ITP) and others. Haemophilia segment dominated the global market share and was valued at USD 6.5 billion in 2022.
 

• Haemophilia is a rare bleeding disorder that restricts the normal blood clotting. The segment growth is attributed to increasing prevalence of haemophilia in developed and underdeveloped countries. According to the data published by World Federation of Haemophilia in 2020, around 209,614 people are living with haemophilia across 120 countries in the world. Adding to this, haemophilia A is most prevalent type of condition. Therefore, growing prevalence of haemophilia coupled with large patient pool will significantly influence the plasma derived therapy demand during the analysis period to reach over USD 13.3 billion by the year 2032.
   

North America market held over 52.2 % business share in 2022 and is projected to experience remarkable growth during the foreseeable future.
 

• Favourable government initiatives and expanding coverage of plasma collection centres by leading market players will offer growth opportunities to the market. Furthermore, increasing awareness about plasma derived therapies among blood donors, and favourable initiatives undertaken by major market players to stimulate blood donation in the region will accelerate the regional revenue trends.
   
• Adding to this, U.S. market dominated the North America plasma derived therapy industry in 2022 with significant demand as well as high plasma volume in the region. Increase in number of patients with rare diseases has strengthened the growth potential of market players operating in the country.
   

Plasma Derived Therapy Market Share

Some of the prominent business players operating in the plasma derived therapy industry include CSL Behring, Takeda Pharmaceutical Company Limited, Biotest AG, Octapharma, BPL, ADMA Biologics, Grifols, SA, Kedrion, Kamada Pharmaceuticals, SK Plasma, Pfizer, among others. These market players are adopting various inorganic growth strategies to gain market share and sustainable competitive advantage.

Market players operating in the plasma derived therapy is as mentioned below:

• CSL Behring
• Takeda Pharmaceutical Company Limited.
• Biotest AG
• Octapharma
• BPL
• ADMA Biologics
• Grifols, SA
• Kedrion
• Kamada Pharmaceuticals
• SK Plasma
• Pfizer, Inc.
   

Plasma Derived Therapy Industry News:

• In July 2020, Grifols one of the leading plasma-derived medicines producer signed agreement with GC Pharma to acquire Montreal-based plasma fractionation facility along with other 11 U.S.-based plasma collection centres, and two purification facilities. This strategic move helped the company to enhance its market revenue along with maintaining its leading position in the industry.
   
• In March 2020, Takeda Pharmaceutical Company Limited initiated the development process of anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG)- TAK-888 for treating Corona Virus (COVID-19). Such initiatives undertaken by pharmaceutical companies accelerated the treatment development procedure against Covid-19. Thus, leading to effective disease management.
   

The plasma derived therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product, 2018 – 2032 (USD Million)

• Immunoglobulins
• Coagulation factors
• Albumin
• Other products

By Application, 2018 – 2032 (USD Million)

• Haemophilia
• Primary immunodeficiency diseases
• Idiopathic/Immune thrombocytopenic purpura (ITP)
• Other applications

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East & Africa